Women First HealthCare acquires Vaniqa, plans relaunch

San Diego - With its acquisition from Bristol-Myers Squibb of worldwide rights and title to Vaniqa (eflornithine hydrochloride) Cream, Women First HealthCare plans to take another pass at providing women with hirsutism a pharmaceutical alternative.

Related Videos
Related Content

Dermal Infusions and Injections Lead to Improved Skin Quality

March 31st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 27-31

March 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

What's Trending in Skin Care: March 2023

March 31st 2023

Treating Dermatological Conditions by Going Beyond the Skin

March 31st 2023

Dermal Infusions and Injections Lead to Improved Skin Quality

March 31st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 27-31

March 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

What's Trending in Skin Care: March 2023

March 31st 2023

Treating Dermatological Conditions by Going Beyond the Skin

March 31st 2023

Dermal Infusions and Injections Lead to Improved Skin Quality

March 31st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 27-31

March 31st 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

What's Trending in Skin Care: March 2023

March 31st 2023

Treating Dermatological Conditions by Going Beyond the Skin

March 31st 2023
© 2023 MJH Life Sciences

All rights reserved.